Precigen posts first quarterly profit as PAPZIMEOS revenue more than doubles
Second-quarter net revenue of $53.1 million drove net income of $20.1 million, and the company said cash on hand plus product sales should carry it to cash flow break-even by year-end 2026.
Precigen reported second-quarter 2026 results on August 4, 2026, with PAPZIMEOS net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter1. The company said PAPZIMEOS revenue propelled the company to quarterly profitability1.
On the regulatory and access front, PAPZIMEOS was granted seven years of market exclusivity by the FDA, providing long-term protection against prospective competition1, and the Centers for Medicare and Medicaid Services assigned permanent J-code, J3404, to PAPZIMEOS, effective April 1, 20261. PAPZIMEOS has payer coverage across approximately 315 million US lives through private health plans, Medicare, and Medicaid, representing nearly 100% of insured lives nationwide.1 An expert position paper sponsored and published by the Recurrent Respiratory Papillomatosis Foundation and authored by 16 leading RRP physicians recommended PAPZIMEOS as the first-line standard of care for adults with RRP in the United States.1
Internationally, the European Medicines Agency has validated and is reviewing the Marketing Authorization Application submitted in November 2025 for zopapogene imadenovec for the treatment of adults with RRP1, and PAPZIMEOS has been granted orphan drug designation from the European Commission1.
On the pipeline, an open-label study evaluating redosing efficacy of zopapogene imadenovec in adults with RRP is currently enrolling under clinical trial identifier NCT065384801. For PRGN-2009, Phase 2 trials under a cooperative research and development agreement with the National Cancer Institute in newly diagnosed HPV-associated oropharyngeal cancer are ongoing, along with a multicenter Phase 2 trial combining PRGN-2009 with pembrolizumab in recurrent/metastatic cervical cancer1. The company said it plans to provide an update on progress across the AdenoVerse portfolio, including PRGN-2009, by the end of the year1.
On finances, cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.